Transatlantic Cooperation in Stemming the Spread of Falsified Medications     Print
Thursday, 25 October 2012

On October 25, 2012, The European Institute, in cooperation with the Embassy of Belgium and the Embassy of Switzerland held a special seminar on transatlantic cooperation in stemming the spread of falsified medications.  Mark Witzal, Deputy Director of the National Intellectual Property Rights Coordination Center, U.S. Immigrations and Customs Enforcement, Homeland Security Investigations presented the keynote address.  Panelists in the first session: Bernard Frahi, Vice President for Corporate Economic Security at Sanofi; Ambassador Richard Kauzlarich, Deputy Director at the Terrorism, Transnational Crime & Corruption Center and Adjunct Professor at George Mason University’s School of Public Policy; and Jeffrey Gren, Director of the Office of Health and Consumer Goods at the U.S. Department of Commerce discussed the security, economic and public health risks of falsified medications.  The panel was moderated by Susan Reardon, Director of International Policy, Worldwide Government Affairs and Policy at Johnson & Johnson.  Panelists in the second session: John Roth, Director of the Office of Criminal Investigations at the U.S. Food and Drug Administration; Patrick Byrne, Europol Senior Representative and Head of Europol Delegation at the Delegation of the European Union to the United States; Chief Commissioner Patrick Stevens, Counselor and Belgian Police Liaison Officer at the Embassy of Belgium; Kelley Friedgen, Senior Corporate Counsel at Genentech and Legal Advisor to the Genentech Counterfeit Prevention and Response Task Force; and Jeannie Salo, Director for Global Anti-Counterfeiting, Office of International Government Affairs at Eli Lilly and Company examined public and private sector solutions to the fast-growing falsified medications problem.  This panel was moderated by Frédéric Badey, Senior Director, International Public Affairs Coordination, Sanofi.